Adverse Event Collection Recommendations

Project Scope 

This project team will create a White Paper with recommendations for Adverse Event Collection Instructions, with a focus on Phase 2-4 clinical trials. This project will build upon a paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices.

Project LeadsEmails

Aimee Basile, Otsuka Pharmaceutical

Aimee.Basile@otsuka-us.com

Mary Nilsson, Eli Lilly

nilsson_mary_e@lilly.com

Nicola Newton, PHUSE Project Assistant

nicky@phuse.global

CURRENT STATUS Q2 2024

  • Published recommendations in white paper 
Objectives & DeliverablesTimelines
Publish White PaperQ2 2024